Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8832261 | 0.85 | KDM4E (0.54) | GLP1RALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL5821768 | 0.83 | KDM4E (0.46) | GLP1RALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL28085332 | 0.78 | GRIN2D (0.50) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL15567798 | 0.76 | GLP1R (0.47) | GLP1RALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL14465575 | 0.75 | ALOX15 (0.50) | ALDH1A1KDM4EHPGDNPSR1ALOX15 | |
| SCHEMBL15567799 | 0.74 | GLP1R (0.48) | GLP1RALDH1A1NPSR1MAPTNPC1 | |
| SCHEMBL28722407 | 0.74 | KDM4E (0.45) | GLP1RALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL9703575 | 0.73 | GRIN2D (0.63) | GLP1RHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL31413104 | 0.73 | GLP1R (0.49) | GLP1RALDH1A1KDM4ENPSR1MAPT | |
| SCHEMBL31556446 | 0.72 | MAOB (0.47) | ALDH1A1KDM4EHPGDNPC1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2020-02-13 | — | — | US | disclosed |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20170320864-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2017-11-09 | — | — | US | disclosed |
| CN-104718206-B | As insecticide and acaricidal azaindole Methanamide and azaindole thioformamide | 拜尔农作物科学股份公司 | 2017-03-08 | — | — | CN | disclosed |
| US-9550758-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| EP-2663561-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2015-07-23 | — | — | US | disclosed |
| US-8865712-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-8637508-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | disclosed |
| EP-2663561-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| CN-103403001-A | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2013-11-20 | — | — | CN | disclosed |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
| WO-2012095469-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | GLP1R 457/4885ALDH1A1 500/4885KDM4E 3189/4885 |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | GLP1R 242/4885ALDH1A1 627/4885KDM4E 3106/4885 |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | GLP1R 457/4885ALDH1A1 500/4885KDM4E 3189/4885 |
| US-20150203481-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | GLP1R 242/4885ALDH1A1 627/4885KDM4E 3106/4885 |
| US-20170320864-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | GLP1R 242/4885ALDH1A1 627/4885KDM4E 3106/4885 |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | GLP1R 457/4885ALDH1A1 500/4885KDM4E 3189/4885 |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | GLP1R 242/4885ALDH1A1 627/4885KDM4E 3106/4885 |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | GLP1R 242/4885ALDH1A1 627/4885KDM4E 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.